Evidence map›Paper›PMID 30140916›Full record

Observational studyAnnals of internal medicine2018

HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study.

Robin M Nance, J A Chris Delaney, Jane M Simoni, Ira B Wilson, Kenneth H Mayer, Bridget M Whitney, Frances M Aunon, Steven A Safren, Michael J Mugavero, W Christopher Mathews and 10 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Annals of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Tracking HIV Through Wastewater: Ethical Considerations in Public Health Surveillance.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Robin M NanceUniversity of Washington, Seattle, Washington (R.M.N., J.C.D., J.M.S., B.M.W., F.M.A., R.J.F., M.M.K., H.M.C.).
J A Chris DelaneyUniversity of Washington, Seattle, Washington (R.M.N., J.C.D., J.M.S., B.M.W., F.M.A., R.J.F., M.M.K., H.M.C.).
Jane M SimoniUniversity of Washington, Seattle, Washington (R.M.N., J.C.D., J.M.S., B.M.W., F.M.A., R.J.F., M.M.K., H.M.C.).
Ira B WilsonBrown University, Providence, Rhode Island (I.B.W.).
Kenneth H MayerHarvard Medical School and Fenway Institute, Boston, Massachusetts (K.H.M.).
Bridget M WhitneyUniversity of Washington, Seattle, Washington (R.M.N., J.C.D., J.M.S., B.M.W., F.M.A., R.J.F., M.M.K., H.M.C.).
Frances M AunonUniversity of Washington, Seattle, Washington (R.M.N., J.C.D., J.M.S., B.M.W., F.M.A., R.J.F., M.M.K., H.M.C.).
Steven A SafrenUniversity of Miami, Miami, Florida, and Fenway Institute, Boston, Massachusetts (S.A.S.).
Michael J MugaveroUniversity of Alabama at Birmingham, Birmingham, Alabama (M.J.M., M.S.S.).
W Christopher MathewsUniversity of California, San Diego, San Diego, California (W.C.M.).
Katerina A ChristopoulosUniversity of California, San Francisco, San Francisco, California (K.A.C.).
Joseph J EronUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.J.E., S.N.).
Sonia NapravnikUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.J.E., S.N.).
Richard D MooreJohns Hopkins University, Baltimore, Maryland (R.D.M., B.L.).
Benigno RodriguezCase Western Reserve University, Cleveland, Ohio (B.R.).
Bryan LauJohns Hopkins University, Baltimore, Maryland (R.D.M., B.L.).
Rob J FredericksenUniversity of Washington, Seattle, Washington (R.M.N., J.C.D., J.M.S., B.M.W., F.M.A., R.J.F., M.M.K., H.M.C.).
Michael S SaagUniversity of Alabama at Birmingham, Birmingham, Alabama (M.J.M., M.S.S.).
Mari M KitahataUniversity of Washington, Seattle, Washington (R.M.N., J.C.D., J.M.S., B.M.W., F.M.A., R.J.F., M.M.K., H.M.C.).
Heidi M CraneUniversity of Washington, Seattle, Washington (R.M.N., J.C.D., J.M.S., B.M.W., F.M.A., R.J.F., M.M.K., H.M.C.).

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Grace C. John-Stewart · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Bryan Lau · 2012 to 2026
$67.0M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Tracking and Evaluation CoreU54GM115677 · NIGMS · BROWN UNIVERSITY · PI SCHMID, CHRISTOPHER H. · 2016 to 2025
$45.0M
VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)U01AA020793 · NIAAA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., LAU, BRYAN · 2011 to 2020
$5.8M
Integration of Evidence-based Alcohol Interventions into HIV CareU01AA020802 · NIAAA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CROPSEY, KAREN L, MUGAVERO, MICHAEL J · 2011 to 2020
$4.2M
1/4 Alcohol Research Consortium in HIV-Administrative Core (ARCH-AC)U24AA020801 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI CHANDER, GEETANJALI, MCCAUL, MARY E · 2011 to 2021
$3.5M
NIAAA NIH HHS U01 AA020793NIAAA NIH HHS U01 AA020802NIAAA NIH HHS U24 AA020801NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI094189NIAID NIH HHS R24 AI067039NIAID NIH HHS T32 AI007140NIDA NIH HHS U01 DA036935NIGMS NIH HHS U54 GM115677
6 · The paper itself

Abstract

Background: Because HIV viral suppression is essential for optimal outcomes and prevention efforts, understanding trends and predictors is imperative to inform public health policy. Objective: To evaluate viral suppression trends in people living with HIV (PLWH), including the relationship of associated factors, such as demographic characteristics and integrase strand transfer inhibitor (ISTI) use. Design: Longitudinal observational cohort study. Setting: 8 HIV clinics across the United States. Participants: PLWH receiving clinical care. Measurements: To understand trends in viral suppression (≤400 copies/mL), annual viral suppression rates from 1997 to 2015 were determined. Analyses were repeated with tests limited to 1 random test per person per year and using inverse probability of censoring weights to address loss to follow-up. Joint longitudinal and survival models and linear mixed models of PLWH receiving antiretroviral therapy (ART) were used to examine associations between viral suppression or continuous viral load (VL) levels and demographic factors, substance use, adherence, and ISTI use. Results: Viral suppression increased from 32% in 1997 to 86% in 2015 on the basis of all tests among 31 930 PLWH. In adjusted analyses, being older (odds ratio [OR], 0.76 per decade [95% CI, 0.74 to 0.78]) and using an ISTI-based regimen (OR, 0.54 [CI, 0.51 to 0.57]) were associated with lower odds of having a detectable VL, and black race was associated with higher odds (OR, 1.68 [CI, 1.57 to 1.80]) (P < 0.001 for each). Similar patterns were seen with continuous VL levels; when analyses were limited to 2010 to 2015; and with adjustment for adherence, substance use, or depression. Limitation: Results are limited to PLWH receiving clinical care. Conclusion: HIV viral suppression rates have improved dramatically across the United States, which is likely partially attributable to improved ART, including ISTI-based regimens. However, disparities among younger and black PLWH merit attention. Primary Funding Source: National Institutes of Health.

Indexed as

Viral LoadAdultAge FactorsAnti-HIV AgentsDepressionFemaleHIV InfectionsHIV Integrase InhibitorsHumansLongitudinal StudiesMaleMedication AdherenceMiddle AgedRace FactorsSubstance-Related DisordersUnited StatesAnti-HIV AgentsHIV Integrase Inhibitors

Identifiers

PMID30140916
PMCPMC6388406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.